EB-108

EB-108 is an investigational biologic therapy being developed by Eluminex Biosciences for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). As part of Eluminex's ophthalmic pipeline, EB-108 is a recombinant protein designed to address vision-threatening retinal diseases. While the specific molecular targets of EB-108 have not been publicly disclosed in detail, the agent is part of a portfolio that includes both biosimilars and innovative multi-specific fusion antibodies aimed at improving therapeutic outcomes over current standard-of-care anti-VEGF monotherapies. The drug is currently in the early stages of development, following the company's lead assets such as EB-101 and EB-105.